Del Fabro, V.; Di Giorgio, M.A.; Leotta, V.; Duminuco, A.; Bellofiore, C.; Markovic, U.; Romano, A.; Bulla, A.; Curto Pelle, A.; Elia, F.;
et al. Lenalidomide plus Dexamethasone Combination as First-Line Oral Therapy of Multiple Myeloma Patients: A Unicentric Real-Life Study. Cancers 2023, 15, 4036.
https://doi.org/10.3390/cancers15164036
AMA Style
Del Fabro V, Di Giorgio MA, Leotta V, Duminuco A, Bellofiore C, Markovic U, Romano A, Bulla A, Curto Pelle A, Elia F,
et al. Lenalidomide plus Dexamethasone Combination as First-Line Oral Therapy of Multiple Myeloma Patients: A Unicentric Real-Life Study. Cancers. 2023; 15(16):4036.
https://doi.org/10.3390/cancers15164036
Chicago/Turabian Style
Del Fabro, Vittorio, Mary Ann Di Giorgio, Valerio Leotta, Andrea Duminuco, Claudia Bellofiore, Uros Markovic, Alessandra Romano, Anna Bulla, Angelo Curto Pelle, Federica Elia,
and et al. 2023. "Lenalidomide plus Dexamethasone Combination as First-Line Oral Therapy of Multiple Myeloma Patients: A Unicentric Real-Life Study" Cancers 15, no. 16: 4036.
https://doi.org/10.3390/cancers15164036
APA Style
Del Fabro, V., Di Giorgio, M. A., Leotta, V., Duminuco, A., Bellofiore, C., Markovic, U., Romano, A., Bulla, A., Curto Pelle, A., Elia, F., Di Raimondo, F., & Conticello, C.
(2023). Lenalidomide plus Dexamethasone Combination as First-Line Oral Therapy of Multiple Myeloma Patients: A Unicentric Real-Life Study. Cancers, 15(16), 4036.
https://doi.org/10.3390/cancers15164036
